<DOC>
	<DOCNO>NCT00418886</DOCNO>
	<brief_summary>Non-small cell lung cancer ( NSCLC ) treat drug kill tumour cell , stop dividing , stop growth blood supply cancer need grow spread . Clinical research show drug inhibit vascular endothelial growth factor receptor ( VEGFR ) epidermal growth factor receptor ( EGFR ) signal increase overall survival patient advance non-small cell lung cancer ( NSCLC ) . Preclinical study show vandetanib ( ZD6474 ) inhibitor VEGFR EGFR signal . Giving vandetanib may therefore inhibit growth cancer cell block blood supply stop divide . This lung cancer study investigate add vandetanib Alimta ( pemetrexed ) effective Alimta ( pemetrexed ) alone .</brief_summary>
	<brief_title>Efficacy Study Comparing ZD6474 Combination With Pemetrexed Pemetrexed Alone 2nd Line NSCLC Patients</brief_title>
	<detailed_description>This randomized phase III non-small cell lung cancer clinical trial study effect Alimta ( pemetrexed ) plus vandetanib see well combination work compare Alimta ( pemetrexed ) alone patient previously treat non-small cell lung cancer ( NSCLC ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Provision inform consent Female male age 18 year Histologic cytologic confirmation locally advance metastatic NSCLC ( stage IIIB IV ) entry study Failure 1st line anticancer therapy ( either radiological documentation disease progression due toxicity ) subsequent relapse disease follow 1st line therapy WHO Performance status 0 2 One measurable lesion least 10 mm long diameter ( LD ) spiral CT scan 20 mm conventional technique accord RECIST criterion . Previously irradiate lesion consider measurable . Life expectancy 12 week longer Negative pregnancy test woman childbearing potential Mixed small cell nonsmall cell lung cancer histology Patients receive 2ndline subsequent anticancer therapy Prior treatment pemetrexed Prior treatment VEGFR TKIs ( previous treatment bevacizumab [ Avastin ] permit ) Known suspect brain metastasis spinal cord compression , unless treat least 4 week entry , stable without steroid treatment 10 day The last radiation therapy within 4 week start study therapy , include local palliative radiation The last dose prior chemotherapy anticancer therapy discontinue less 3 week start study therapy ( 6 week nitrosoureas , mitomycin , suramin ) Major surgery within 4 week entry , incompletely heal surgical incision Neutrophils &lt; 1.5 x 109/L platelet &lt; 100 x 109/L Serum bilirubin &gt; 1.5 x upper limit reference range ( ULRR ) Creatinine clearance &lt; 50 ml/min calculate either Cockcroft Gault , 24 hour urine collection , EDTA scan validate method Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 x ULRR absence liver metastasis , &gt; 5 x ULRR presence liver metastases Alkaline phosphatase ( ALP ) &gt; 2.5 x ULRR absence liver metastasis , &gt; 5 x ULRR presence liver metastases Current active gastrointestinal disease may affect ability patient absorb ZD6474 tolerate diarrhoea Evidence severe uncontrolled systemic disease concurrent condition investigator 's opinion make undesirable patient participate study would jeopardize compliance protocol Any unresolved toxicity great CTCAE Grade 2 previous anticancer therapy Significant cardiovascular event ( e.g. , myocardial infarction , superior vena cava [ SVC ] syndrome ) , New York Heart Association [ NYHA ] classification heart disease ≥2 within 3 month entry , presence cardiac disease opinion Investigator increase risk ventricular arrhythmia History arrhythmia ( multifocal premature ventricular contraction [ PVCs ] , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) symptomatic require treatment ( CTCAE grade 3 ) asymptomatic sustain ventricular tachycardia . Atrial fibrillation , control medication exclude Congenital long QT syndrome 1st degree relative unexplained sudden death 40 year age QT prolongation medication require discontinuation medication Presence leave bundle branch block ( LBBB ) QTc Bazett 's correction unmeasurable ≥ 480 msec screen ECG ( Note : If patient QTc interval ≥480 msec screen ECG , screen ECG may repeat twice [ least 24 hour apart ] . The average QTc three screen ECGs must &lt; 480 msec order patient eligible study ) Patients receive drug risk QTc prolongation eligible QTc &lt; 460 msec . Potassium &lt; 4.0 mmol/L despite supplementation ; serum calcium ( ionize adjust albumin ) , magnesium normal range despite supplementation Women pregnant breastfeed Any concomitant medication may cause QTc prolongation induce Torsades de Pointes induce CYP3A4 function . Drugs risk QTc prolongation , investigator 's opinion discontinue , allow , QTc &lt; 460 msec Hypertension control medical therapy ( systolic blood pressure great 160 millimetre mercury [ mmHg ] diastolic blood pressure great 100 mmHg ) Previous current malignancy histology within last 5 year , exception situ carcinoma cervix adequately treat basal cell squamous cell carcinoma skin Treatment nonapproved investigational drug within 30 day Day 1 study treatment Concomitant use yellow fever vaccine live attenuate vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
</DOC>